Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
IPO Year:
Exchange: NASDAQ
Website: fennecpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2026 | $16.00 | Buy | B. Riley Securities |
| 1/9/2026 | Overweight | Piper Sandler | |
| 11/22/2022 | $9.00 → $12.00 | Neutral → Overweight | Cantor Fitzgerald |
| 9/7/2022 | $11.00 | Overweight | CapitalOne |
| 8/8/2022 | $14.00 | Buy | Craig Hallum |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
B. Riley Securities initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $16.00
Piper Sandler initiated coverage of Fennec Pharmaceuticals with a rating of Overweight
Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously
CapitalOne initiated coverage of Fennec Pharmaceuticals with a rating of Overweight and set a new price target of $11.00
Craig Hallum resumed coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00
HC Wainwright & Co. reiterated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $15.00 previously
Craig-Hallum initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $17.00
Maxim Group initiated coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
S-8 - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
10-Q - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
144 - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
SCHEDULE 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
DEF 14A - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)
Fastest customizable press release news feed in the world
RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards ("ISOs") to purchase an aggregate of 10,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 15, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq L
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025. Detailed results of the vote for the election of directors are set out below: Name of NomineeVotes For% Votes ForVotes Withheld% Votes WithheldDr. Khalid Islam13,858,13197.84%304,7602.15%Mr. Chris A. Rallis13,808,79297.49%354,0992.50%Mr. Marco Brughera13,807,50197.49%355,3902.50%Dr. Jodi Cook13,259,89493.62%902,9976.37%Mr. Jeff Hackman13,4
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approximately Six Hours After Cisplatin Can Be Safe & Easily Integrated into Patient Care and Does Not Compromise Cisplatin's Established Antitumor Activity ~ RESEARCH TRIANGLE PARK, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on May 11, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of stock option awards ("Stock Options") to purchase an aggregate of 50,000 of the Company's common shares to three new non-executive employees of the Company with a grant date of May 18, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The Stock Options consist of incentive stock options to purchase an aggregate of 49,141 shares and nonqualified stock options to pur
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/2iptdco4Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3
– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced that four abstracts evaluating PEDMARK® (sodium thiosulfate injection) were accepted as part of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting program, taking place May 29-June 2, 2026 in Chicago, IL. PEDMARK® is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors, and is also recognized by the
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations ~ RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with hea
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards ("ISOs") to purchase an aggregate of 377,500 of the Company's common shares to 24 new non-executive employees of the Company with a grant date of March 31, 2026 under the Company's 2026 Equity Inducement Plan (the "Inducement Plan"). The ISOs were granted as inducements material to the employees entering into employment with the Company in accordance with Nas
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Toplin
Live Leadership Updates
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c
Live finance-specific insights
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a sp
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/2iptdco4Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Toplin
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Tuesday, March 24, 2026Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/3crq898eParticipant Link: https://register-conf.media-server.com/register/BIb7d9f04377fd4
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany with Additional EU Launches Planned ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Half of 2025 with Evaluation of Both Registration and Partnering or Licensing Expected Thereafter ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, August 14, 2025Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/de4jxxzj Participant Link: https://register-conf.media-server.com/register/BI3e750b95d06c439ea560b
~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Time:8:30 a.m. ETWebcast Link:https://edge.media-server.com/mmc/p/nb5vbq6oParticipant Link:https://register-conf.media-server.com/register/BIbc2eaa3f157d4c6891b71246a83bdb02 To access the li
~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term Investments ~ ~ Completed Early Repayment of $13 Million of the Company's Convertible Debt Facility ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ PEDMARQSI® Now Commercially Available to Patients and Healthcare Providers in the United Kingdom and Germany ~ ~ Japan Clini
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date:Monday, March 10, 2025Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/7bafbd7q To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Event
This live feed shows all institutional transactions in real time.
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)
SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)